<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997902</url>
  </required_header>
  <id_info>
    <org_study_id>KO-TIP-013</org_study_id>
    <nct_id>NCT04997902</nct_id>
  </id_info>
  <brief_title>Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)</brief_title>
  <official_title>A Phase 1/2 Open-label, Biomarker-defined Cohort Trial to Evaluate the Safety, Determine the Recommended Combination Dosing, and Assess Early Antitumor Activity of Tipifarnib and Alpelisib for the Treatment of Adult Participants Who Have HRAS-overexpressing and/or PIK3CA-mutated and/or - Amplified Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kura Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kura Oncology, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and&#xD;
      alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous&#xD;
      cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated&#xD;
      and/or PIK3CA-amplified.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the recommended dose and regimen and evaluate the safety and tolerability of the combination of tipifarnib and alpelisib</measure>
    <time_frame>DLTs will be evaluated during the first 28 days (1 cycle) of combination therapy</time_frame>
    <description>Rate of DLT per dose level and Descriptive statistics of adverse events per the NCI CTCAE v 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Overall confirmed response rate (CR + PR) and Median duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Disease control rate (CR + PR + SD), Median duration of disease control, Rate of SD, Median duration of SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of tipifarnib and alpelisib when administered in combination</measure>
    <time_frame>Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.</time_frame>
    <description>Peak drug concentration for single dose and multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of tipifarnib and alpelisib when administered in combination</measure>
    <time_frame>Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.</time_frame>
    <description>Time to reach peak concentration following drug administration for single dose and multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-last) of tipifarnib and alpelisib when administered in combination</measure>
    <time_frame>Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.</time_frame>
    <description>Area under the concentration-time curve from time zero to time of last measurable concentration for single dose and multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(tau) of tipifarnib and alpelisib when administered in combination</measure>
    <time_frame>Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.</time_frame>
    <description>Area under the concentration-time curve during a dosage interval for single dose and multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-infinity) of tipifarnib and alpelisib when administered in combination</measure>
    <time_frame>Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.</time_frame>
    <description>Area under the concentration-time curve from time zero to infinity for single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of tipifarnib and alpelisib when administered in combination</measure>
    <time_frame>Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.</time_frame>
    <description>Apparent total clearance of the drug after administration for single dose and multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of tipifarnib and alpelisib when administered in combination</measure>
    <time_frame>Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.</time_frame>
    <description>Apparent volume of distribution after administration for single dose and multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of tipifarnib and alpelisib when administered in combination</measure>
    <time_frame>Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.</time_frame>
    <description>Time required for the amount of drug in the body to decrease by half for single dose and multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of tipifarnib and alpelisib when administered in combination</measure>
    <time_frame>Blood samples will be collected on day 1 and day 2 of Cycle 1 and Cycle 2, and on day 1 of Cycle 3 through Cycle 6. Each cycle is 28 days.</time_frame>
    <description>Ratio of accumulation of a drug after multiple doses compared to a single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity in terms of PFS and rate of PFS at 6 months</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Median PFS and Proportion of participants alive and without progression at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) and rate of OS at 12 months</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Median OS and Proportion of participants alive at 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>PIK3CA-dependent (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult participants with R/M HNSCC whose tumors harbor PI3KCA (activating) mutations and/or amplifications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HRAS-dependent (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult participants with R/M HNSCC whose tumors have increased HRAS dependency, defined as HRAS overexpression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipifarnib</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>HRAS-dependent (Cohort 2)</arm_group_label>
    <arm_group_label>PIK3CA-dependent (Cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpelisib</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>HRAS-dependent (Cohort 2)</arm_group_label>
    <arm_group_label>PIK3CA-dependent (Cohort 1)</arm_group_label>
    <other_name>BYL719</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years of age.&#xD;
&#xD;
          2. Histologically confirmed head and neck cancer of squamous histology not amenable to&#xD;
             local therapy with curative intent (surgery or radiation therapy with or without&#xD;
             chemotherapy).&#xD;
&#xD;
          3. Documented treatment failure from at least 1 prior systemic therapy in the R/M&#xD;
             setting, unless determined not appropriate.&#xD;
&#xD;
          4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.&#xD;
&#xD;
          5. Has a tumor that is dependent upon HRAS and/or PIK3CA.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          7. Acceptable liver, renal, endocrine, and hematologic function.&#xD;
&#xD;
          8. Must be able to swallow alpelisib whole tablet or oral suspension containing crushed&#xD;
             tablets. Feeding tube may not be used for alpelisib administration.&#xD;
&#xD;
          9. Other protocol defined inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed salivary gland, thyroid, (primary) cutaneous squamous or&#xD;
             nonsquamous histologies (eg, mucosal melanoma).&#xD;
&#xD;
          2. Ongoing treatment with certain anticancer agents.&#xD;
&#xD;
          3. Prior treatment (at least 1 full treatment cycle) with an FTI or PI3K, mTOR, or AKT&#xD;
             inhibitor.&#xD;
&#xD;
          4. Received treatment for unstable angina, myocardial infarction, and/or cerebro-vascular&#xD;
             attack within the prior 6 months.&#xD;
&#xD;
          5. Non-tolerable Grade 2, or â‰¥ Grade 3 neuropathy or evidence of unstable neurological&#xD;
             symptoms within 4 weeks of Cycle 1 Day 1.&#xD;
&#xD;
          6. Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1,&#xD;
             without complete recovery.&#xD;
&#xD;
          7. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic&#xD;
             therapy.&#xD;
&#xD;
          8. Participant with an established diagnosis of diabetes mellitus Type 1 or not&#xD;
             controlled Type 2.&#xD;
&#xD;
          9. Participant has impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of the trial drugs based on Investigator&#xD;
             discretion.&#xD;
&#xD;
         10. Participant has currently documented pneumonitis/interstitial lung disease.&#xD;
&#xD;
         11. Participant has a history of severe cutaneous reaction, such as Stevens-Johnson&#xD;
             Syndrome (SJS), Erythema Multiforme (EM), Toxic Epidermal Necrolysis (TEN), or Drug&#xD;
             Reaction with Eosinophilia and Systemic Symptoms (DRESS).&#xD;
&#xD;
         12. Other protocol defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>617-588-3755</phone>
    <email>KO-TIP-013@kuraoncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lake Nona DDU (Florida Cancer Specialists)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar A. Perez, MD</last_name>
      <phone>689-216-8500</phone>
      <email>Cesar.PerezBatista@flcancer.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HRAS</keyword>
  <keyword>PIK3CA</keyword>
  <keyword>PI3K</keyword>
  <keyword>Tipifarnib</keyword>
  <keyword>Alpelisib</keyword>
  <keyword>R/M HNSCC (Recurrent/metastatic Head and Neck Squamous Cell Carcinoma)</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>SCCHN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

